2,168 reports of this reaction
7.0% of all BENDAMUSTINE HCL reports
#1 most reported adverse reaction
DISEASE PROGRESSION is the #1 most commonly reported adverse reaction for BENDAMUSTINE HCL, manufactured by Meitheal Pharmaceuticals Inc.. There are 2,168 FDA adverse event reports linking BENDAMUSTINE HCL to DISEASE PROGRESSION. This represents approximately 7.0% of all 30,914 adverse event reports for this drug.
Patients taking BENDAMUSTINE HCL who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is moderately reported among BENDAMUSTINE HCL users, representing a notable but not dominant share of adverse events.
In addition to disease progression, the following adverse reactions have been reported for BENDAMUSTINE HCL:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 2,168 FDA reports for BENDAMUSTINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 7.0% of all adverse event reports for BENDAMUSTINE HCL, making it one of the most commonly reported side effect.
If you experience disease progression while taking BENDAMUSTINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.